ATE439380T1 - Methoden zur herstellung humaner monoklonaler antikörper - Google Patents

Methoden zur herstellung humaner monoklonaler antikörper

Info

Publication number
ATE439380T1
ATE439380T1 AT01903344T AT01903344T ATE439380T1 AT E439380 T1 ATE439380 T1 AT E439380T1 AT 01903344 T AT01903344 T AT 01903344T AT 01903344 T AT01903344 T AT 01903344T AT E439380 T1 ATE439380 T1 AT E439380T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
methods
human monoclonal
producing human
cell type
Prior art date
Application number
AT01903344T
Other languages
English (en)
Inventor
Ronghao Li
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE439380T1 publication Critical patent/ATE439380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01903344T 2000-01-26 2001-01-26 Methoden zur herstellung humaner monoklonaler antikörper ATE439380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/491,894 US6541225B1 (en) 2000-01-26 2000-01-26 Methods and compositions for generating human monoclonal antibodies
PCT/US2001/002588 WO2001055216A1 (en) 2000-01-26 2001-01-26 Methods and compositions for generating human monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE439380T1 true ATE439380T1 (de) 2009-08-15

Family

ID=23954109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903344T ATE439380T1 (de) 2000-01-26 2001-01-26 Methoden zur herstellung humaner monoklonaler antikörper

Country Status (10)

Country Link
US (3) US6541225B1 (de)
EP (1) EP1255780B1 (de)
JP (1) JP4790959B2 (de)
KR (1) KR20020073185A (de)
CN (1) CN100491397C (de)
AT (1) ATE439380T1 (de)
AU (2) AU2001231172B2 (de)
CA (1) CA2398284A1 (de)
DE (1) DE60139542D1 (de)
WO (1) WO2001055216A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6794141B2 (en) * 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
JP2007514752A (ja) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
KR101295139B1 (ko) * 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
CA2597171A1 (en) * 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Antibodies to oncostatin m receptor
BRPI0607450A2 (pt) * 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
EP2343363A1 (de) * 2005-07-01 2011-07-13 John Schrader Verfahren zur Isolierung von Zellen und Erzeugung monoklonaler Antikörper unter Verwendung einer Einzel-Epitop Mehrfach-Färbung
JP2009521228A (ja) * 2005-12-21 2009-06-04 ヴァックスデザイン コーポレーション 単球の樹状細胞への分化を促進する多孔質膜デバイス
CA2634123C (en) * 2005-12-21 2015-11-24 Vaxdesign Corporation In vitro germinal centers
KR100850416B1 (ko) * 2006-06-21 2008-08-04 남상윤 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법
US7709257B2 (en) * 2006-06-27 2010-05-04 Vax Design Corp. Models for vaccine assessment
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20090104221A1 (en) * 2007-07-06 2009-04-23 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009054556A1 (en) * 2007-10-24 2009-04-30 Sang Yun Nam Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity
WO2009072660A1 (ja) * 2007-12-03 2009-06-11 Kabushiki Kaisya Advance 抗体作製方法
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
TWI477603B (zh) * 2011-01-28 2015-03-21 鴻海精密工業股份有限公司 培育基體之製備方法
EP3363813A1 (de) 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2724157B1 (de) * 2011-06-27 2017-03-08 Valneva Screening-verfahren für zellen
CN102321720B (zh) * 2011-07-28 2014-09-03 万晓春 一种混合细胞培养生产纯人源单克隆抗体的方法
EP2727942A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
EP2727943A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispezifische Antikörper gegen menschliche EGFR, HER2 und HER3
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
US9395367B1 (en) 2016-02-29 2016-07-19 Rarecyte, Inc. Method to identify antigen-specific B cells for antibody development
US9442113B1 (en) 2016-02-29 2016-09-13 Rarecyte, Inc. Method to identify antigen-specific immune cells for therapeutic development
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
EP3241845A1 (de) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanisierte anti-il-1r3-antikörper
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643971A (en) * 1983-03-11 1987-02-17 Sloan-Kettering Institute Monoclonal antibodies to human bladder and ureter cancers and method
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0218158A3 (de) 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Menschlicher monoklonaler Antikörper, B-Zell-Linie für die Herstellung dieses Antikörpers und Verfahren zur Herstellung dieser B-Zell-Linie und Antikörper.
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69126281T2 (de) * 1990-11-26 1997-10-16 Akzo Nobel Nv Verfahren zur Herstellung von Antikörpern
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
JPH09503901A (ja) 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies

Also Published As

Publication number Publication date
CN1420893A (zh) 2003-05-28
DE60139542D1 (de) 2009-09-24
CA2398284A1 (en) 2001-08-02
US20060252124A1 (en) 2006-11-09
US20030109006A1 (en) 2003-06-12
US6541225B1 (en) 2003-04-01
JP2003531578A (ja) 2003-10-28
WO2001055216A1 (en) 2001-08-02
KR20020073185A (ko) 2002-09-19
HK1050695A1 (en) 2003-07-04
EP1255780A1 (de) 2002-11-13
AU3117201A (en) 2001-08-07
EP1255780B1 (de) 2009-08-12
US8137668B2 (en) 2012-03-20
CN100491397C (zh) 2009-05-27
JP4790959B2 (ja) 2011-10-12
AU2001231172B2 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
CY1109683T1 (el) Αντιγονα του streptococcus pyogenes
ATE459651T1 (de) Antigenbindende domäne aus fisch
WO2003034903A3 (en) Psma antibodies and protein multimers
DE69932813D1 (de) Nukleinsäurebindungsproteine
IL211367A0 (en) An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
WO2005028625A3 (en) Consensus/ancestral immunogens
WO2002083738A1 (fr) Anticorps trispecifique monocatenaire cyclique
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
WO2002033116A3 (en) Nucleic acid ligands to the prostate specific membrane antigen
DE60217708D1 (de) Verfahren, um ein elastisches verbundmaterial herzustellen
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
WO2001077291A3 (en) Polynucleotides encoding novel secreted proteins
WO2002063010A3 (en) Method of producing recombinant antibodies against tumors
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
ATE358172T1 (de) Verfahren zur herstellung von olefinen.
ATE296816T1 (de) Verfahren zur herstellung von ethern, vorzugsweise von thf
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
ATE391115T1 (de) Verfahren zur herstellung von diketenacetalen
WO2005049652A3 (en) Methods of generating antibody diversity in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties